HomeAll New Products Listed Chronologically

All New Products Listed Chronologically

Catalog No. Product Name Information Isotype
A2543 Tinurilimab (Anti-CEACAM6 / CD66c) Tinurilimab (Anti-CEACAM6 / CD66c) is an monoclonal antibody targeting against CEACAM6 and CD66c. CEACAM6 is an immune checkpoint regulator suppressing the activity of effector T-cells against tumors. MW: 145.5 KD. Aug 10 2023
A2544 Tusamitamab (Anti-CEACAM5 / CEA / CD66e) Tusamitamab (Anti-CEACAM5 / CEA / CD66e) is an IgG1 monoclonal antibody that targets CEACAM5. Tusamitamab can be used to synthesize Tusamitamab ravtansine, which is a first-in-class humanized antibody-drug conjugate (ADC) that combines Tusamitamab and DM4 (a potent maytansine derivative). MW: 145.5 KD. Aug 10 2023
A2545 Anti-CEACAM1 / CD66a Anti-CEACAM1 / CD66a (CM-24) is a humanized monoclonal immunoglobulin G4 (IgG4) antibody targeting CEACAM1 and CD66a, with potential immunomodulating and antineoplastic activities. It blocks the binding of CEACAM1-expressing cancer cells to CEACAM1-expressing immune cells and abrogates CEACAM1-mediated immunosuppression. MW: 145.5 KD. Aug 10 2023
A2546 Actoxumab (Anti-Cdiff Toxin A) Actoxumab ( (Anti-Cdiff Toxin A) is a antitoxin antibody against C. difficile toxin A by neutralizing TcdA. Actoxumab prevents both the damage to the gut wall and the inflammatory response, which are associated with C. difficile. Actoxumab has synergy effect with Bezlotoxumab targeting TcdB. MW: 145.5 KD. Aug 10 2023
A2547 Anti-CDH6 / K-Cadherin Anti-CDH6 / K-Cadherin (DS-6000a) is a humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting against the tumor-associated antigen cadherin-6. MW: 145.5 KD. Aug 10 2023
A2548 Anti-CDH3 / P-cadherin Anti-CDH3 / P-cadherin (PF-03732010) is a antibody targeting p-cadherin. It binds to and inhibits the activity of p-cadherin which may inhibit tumor cell invasion and proliferation in p-cadherin expressing tumor cells. MW: 145.5 KD. Aug 10 2023
A2549 Anti-CD98 Anti-CD98 (KHK2898) is an antibody targeting CD98. MW: 145.5 KD. Aug 10 2023
A2550 Polatuzumab (Anti-CD79b) Polatuzumab (Anti-CD79b) is a monoclonal antibody which targets CD79b that is found on the surface of B cells. Polatuzumab sticks to the CD79b protein and delivers the chemotherapy compound into the cell. MW: 145.5 KD. Aug 10 2023
A2551 Milatuzumab (Anti-CD74) Milatuzumab (Anti-CD74) is a humanized monoclonal antibody targeting CD74, a integral membrane protein. Milatuzumab causes free radical oxygen generation, and loss of mitochondrial membrane potential. Milatuzumaba also decreases CD20/CD74 aggregates and cell adhesion, to lead to cell death. MW:145.5 KD. Aug 10 2023
A2552 Itolizumab (Anti-CD6) Itolizumab (Anti-CD6) is a humanized recombinant anti-CD6 monoclonal antibody (MAb) targeting the extracellular SRCR distal domain 1 of CD6. Itolizumab reduces T-cell proliferation and inhibits the production of pro-inflammatory cytokines, such as INF-γ, TNFα and IL-6. Itolizumab can be used in the research of psoriasis, rheumatoid arthritis, COVID-19. MW:145.5 KD. Aug 10 2023
A2553 Alemtuzumab (Anti-CD52) Alemtuzumab (Anti-CD52) is a humanized monoclonal antibody targeting against CD52. Alemtuzumab selectively targets the CD52 antigen to induce profound lymphocyte depletion, followed by recovery of T and B cells with regulatory phenotypes. MW:145.5 KD. Aug 10 2023
A2554 Anti-CD46 Anti-CD46 (FOR46) is a human monoclonal antibody targeting against CD46. It specifically targets and binds to a specific conformational epitope on the immune modulatory receptor CD46 expressed on certain tumor cells. MW:145.5 KD. Aug 10 2023
A2555 Bivatuzumab (Anti-CD44v6) Bivatuzumab (Anti-CD44v6) is a humanized monoclonal antibody targeting against CD44v6 that could acts as a sarcoma target for CAR-redirected CIK cells. MW:145.5 KD. Aug 10 2023
A2300 Anti-VEGFR3 / FLT4 Anti-VEGFR3 / FLT4 is a fully-human monoclonal antibody directed against (VEGFR-3; Flt-4) with antiangiogenic activity.Anti-VEGFR3 / FLT4 also plays a critical role in the embryonic vascular system development. Aug 10 2023
A2556 Ibalizumab (Anti-CD4) Ibalizumab (Anti-CD4) is a humanised IgG4 monoclonal antibody, targeting C4. It prevents HIV cell entry by binding to CD4 receptor. Ibalizumab has the potential for HIV-1 infection research. MW:145.5 KD. Aug 10 2023
A2301 Icrucumab (Anti-VEGFR1 / FLT1) Icrucumab (Anti-VEGFR1 / FLT1) is a humanized Anti-VEGFR-1 IgG1 monoclonal antibody, with potential anti-tumor and anti-metastatic agent. It also act as a therapeutic anti-angiogenic agent in different pathological contexts. Aug 10 2023
A2557 Teplizumab (Anti-CD3e) Teplizumab (Anti-CD3e) is a Fc receptor non-binding anti-human CD3 monoclonal antibody. Teplizumab reduces the loss of beta-cell function. Teplizumab can be used in the research of type 1 diabetes. MW:145.5 KD. Aug 10 2023
A2302 Anti-VEGFC Anti-VEGFC is a fully human monoclonal antibody targeting the human vascular endothelial growth factor C (VEGFC or Flt4 ligand) with potential antiangiogenic activity and lymphangiogenesis. It also prevent metastasis. MW :145.5 KD. Aug 10 2023
A2303 Anti-VEGFB Anti-VEGFB (CSL346) is an antibody targeting VEGFA. MW:150 KD. Aug 10 2023
A2559 Galiximab (Anti-CD28L / CD80) Galiximab (Anti-CD28L/CD80) is a primatized immunoglobulin G1 (IgG1) lambda monoclonal antibody targeting against the CD80 antigen. Galiximab has variable regions are primatized (cynomologous monkeys), and the constant regions are human. Galiximab can be used in research of B-cell lymphoma. MW:145.5 KD. Aug 10 2023